Form 4: Rhythm Pharmaceuticals Director Lynn A. Tetrault Executes Stock Option and Sells Shares

Director Lynn A. Tetrault exercised stock options and sold shares of Rhythm Pharmaceuticals, Inc. on August 26, 2024, according to a Form 4 filing with the SEC.

Summary

• On August 26, 2024, Lynn A. Tetrault, a director of Rhythm Pharmaceuticals, Inc., exercised stock options to acquire 4,300 shares of common stock at a price of $18.99 per share.
• Simultaneously, Tetrault sold 4,300 shares of Rhythm Pharmaceuticals common stock at a weighted average price of $50.0067, with individual sales ranging from $50.00 to $50.03 per share.
• Following these transactions, Tetrault directly owns 3,000 shares of Rhythm Pharmaceuticals common stock.
• Tetrault also directly owns 10,700 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The director is selling shares, which could be seen as slightly negative, but the existence of a 10b5-1 plan mitigates this.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, although the pre-arranged trading plan mitigates the impact.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates